Marketing Approval for Slounase® (Hemocoagulase) in China

(Hong Kong, 22 September 2006) - Lee’s Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the Company has obtained from the SFDA of China a Good Manufacturing Practices (GMP) Certificate related to the plant facility and quality assurance system for production of the "Small Volume Parenteral Solutions". As a result, the Company is starting shipment of its new product Slounase® to its distributors over China today.

Slounase® is the forth product developed in-house by the Company's research and development team and it is the only Hemocoagulase in the market that is in small volume injection formulation. Pharmacological studies have shown that the Slounase® is as effective as the imported Hemocoagulase in shortening the bleeding time and reducing loss of blood. Slounase® also demonstrated excellent safety profile during the studies.

Hemocoagulase was first developed in 1936 by an Austria scholar, Klobusitzky, by purify snake venom from Bothopsatrox. Hemocoagulase is an enzyme for treatment of bleeding and its effectiveness has been recognized during the last few decades’ clinical application. In PRC, the market demand of Hemocoagulase is huge with the estimation of a market size of RMB400 million. As the price of the domestic Hemocoagulase is likely to be more competitive than the imported one, it is expected that Slounase® could achieve significant market share in relatively short period of time.

Dr. Benjamin Li, the Chief Executive Officer of the Group comments on this approval by saying that "We’re extremely excited for the launching of this new product and are particularly grateful for the hard work and tireless efforts of our Chinese colleagues. The approval marks the successful development of this new drug and is a compliment to the Group’s pharmaceutical development capabilities. It again ascertains our ability to move technology from benchside to bedside. Furthermore, the launch significantly improves the Group’s revenue growth outlook and its profitability."

About Lee’s

Lee’s Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.

*Safe Harbor Statement*

The statements in this news release, other than the historical financial information, may contain
forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee’s financial condition and results of operations is detailed in Lee’s IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com